RankingsPrimerArbiterPhysicistMathematicianContrarianQESites logClaimsSourcesResearch notes

The Seattle Times (and therapyproducts.net copy), 2026-10-04 (Investigator run 1)

Queries (Google, in Chrome): "Pappas" PAPIMI "pulsed magnetic induction"; Seattle Times 2007 Papimi device FDA Pappas.

Files saved (research/files/): - seattletimes-2007-FDA-EIR-papimi.pdf. Source: https://special.seattletimes.com/s/ABPub/2007/11/14/2004014231.pdf. 18-page fax scan (faxed 11/14/07) of the FDA Establishment Inspection Report on Bio-Energy Services Inc., 17 pp. No text layer; read by tesseract OCR from 200 dpi page images (scratch /tmp/pappas-pt-scratch). Pages 1-11 read; pages 12-17 OCR'd but not read closely. - seattletimes-2007-11-19-FDA-letter-papimi.pdf. Source: https://special.seattletimes.com/s/ABPub/2007/11/19/2004023297.pdf. 2 pp, scanned FDA letter, OCR. - seattletimes-2007-11-19-papimi-timeline.pdf. Source: https://special.seattletimes.com/s/ABPub/2007/11/19/2004022825.pdf. Graphic: "The PAP-IMI in the U.S.", total 89 units by state; timeline 1995-2007. - seattletimes-2007-11-19-public-never-warned.pdf. Source: https://therapyproducts.net/pulsed-electromagnetic-devices/wp-content/uploads/2017/03/SeattleTimes-PAPIMI.pdf. Print of the article, original URL http://seattletimes.nwsource.com/html/localnews/2004022178_miracle19m2.html. Hosted by Matrix Therapy Products, a seller of a different PEMF device (an interested party hosting a copy).

FDA Establishment Inspection Report (EIR) [web, OCR]

  • Firm: Bio-Energy Services Inc., 18727 Ventura Blvd, Tarzana CA 91356. FEI 3003668912. Inspection dates 8/21, 22, 26 and 9/10/02. "District initiated for cause inspection of a Sponsor-Investigator of an investigational medical device. The device is known as the PAP-IMI or Papimi."
  • In the FDA's words, "The firm claims the device delivers electro-magnetic energy into the body, although the science behind the device is not clear." Study run under non-significant-risk rules.
  • Sponsor/PI: Charles (Chuck) Wallach, CEO. Study terminated by Biomedical Research Institute of America IRB (San Diego) on 06/07/02 for "unanticipated adverse events, commercialization, lack of informed consent, and mis-leading claims". About 37 study sites in at least 12 states. Wallach said 35 US sites and 4 in Canada.
  • "The device is imported from Greece... reportedly manufactured by [redacted] Athens, Greece... reportedly headed by the owner, Dr. Panagiotis (Panos) T. Pappas, owner of the patent (U.S. # 5,556,418)". Declared to US Customs as a "plant and seed germinator". Wallach said he did so because "that designation assured the device could get into the country without being scrutinized as a medical device and that it really could cause seed germination". Port of entry LAX. Current model "600P". Websites www.papimi.com (Wallach) and www.papimi.gr (Pappas).
  • Business history: "The OSCAR database shows a 510(k) was submitted on November 6, 1995 for the 'Pap Ion magnetic inductor'... not cleared because it required unavailable clinical data". Wallach was earlier CEO of "Pap Electrodynamics".
  • p.3: "The science of the output of this device is not clear. The Bio-Energy website implies the output is the full range of the electromagnetic spectrum, including x-rays." Wallach "states Dr. Pappas is the inventor... and that it is being studied in Europe for pain relief."
  • p.4: an infant with rhabdomyosarcoma, taken off chemotherapy by the mother, had received at least 29 PAP-IMI treatments at the Tarzana site.
  • p.5-6: investigational plan: "a non heat producing pulsed diathermy device" for pain intensity, relief, range of motion and swelling; 3-24 treatments over six weeks; pain relief scale 0-11. The FDA notes that analgesic use was not controlled.
  • p.6: informed consent: of 13 files, 8 had no signed consent and 3 were signed after treatment began.
  • p.8: GMP: units arrive unfinished, and Bio-Energy assembles the transformers and rectifiers in the US. No finished-device test records. Bottled water "energized" by the PAP-IMI was sold. Serial no. 1202740R3M3C3MT3PM3F3.
  • p.9: importation: invoice #270 of 6/21/01 names a Greek manufacturer. Other units are marked "Z Electrodynamics". Wallach said both companies were owned by Dr Pappas: "Z" the production division and the other the R&D division. Units sold to investigators (one invoice to Dr David Minkoff, Clearwater FL, 04/24/02). Treatments $60 per half hour or $480 for ten.
  • p.10: advertising: testimonials, a paper by Dr Shri Kant Mishra MD claiming effectiveness for rheumatoid arthritis, lupus and ageing; "Papimi Times" newsletter (July 2002): "micro-pulsing at one-millionth of a second"; a brochure citing "Approval" from Canada's Medical Device Bureau; a brochure on pain relief in animals. A Minkoff annual report mentions two subject deaths not filed as adverse events.
  • p.11: an e-mail says "Dr. Pappas was saying that pre-surgery treatments was shortening the recovery time by one-third to one-half". The PAP-IMIs were CE marked ("Z Electrodynamics declaration of conformity").

FDA letter to Pappas, dated JUN 10 2005 (OCR "JUN 10 205") [web, OCR]

  • To "Panos Pappas, PhD, 11502 North Poema Place, #204, Chatsworth, CA 91311", from Michael E. Marcarelli, PharmD, Director, Division of Bioresearch Monitoring, CDRH.
  • It concerns "clinical investigations of the PAP Ion Magnetic Inductor (PAP-IMI) for the management of arthritic knee pain and for management of myalgias and arthralgias". The TABS IRB (Houston) had judged them non-significant risk. The FDA determined significant risk under 21 CFR 812.3(m) because: 1. "the PAP-IMI device would be considered a Class III non-heating diathermy device that would require Pre-Marketing Approval (PMA)." 2. "The device appears to be capable of delivering 100 watts at 2 apps (2 seconds x 50 Joules) of energy for every two pulses." 3. "Animal studies with the PAP-IMI device resulted in adverse events including 2 Wistar rat deaths and one case of tremor and unsteady coordination in a rat." 4. "Human clinical adverse events have occurred, including 2 cases of tachycardia and one fatal myocardial infarction during treatment with the device."
  • "This device is now considered adulterated" (FDCA 501). Enrolment to stop. Any marketing route requires an IDE.
  • Stakeholder note: FDA is the regulator (an interested party). The 50 J per pulse figure is FDA's reading of the device description, not a measurement reported here.

Timeline graphic [web] (Seattle Times, sources: FDA, California DHS, Seattle Times reporting)

1995 Nov FDA denies request to sell and market; 1999 Oct "Panos Pappas' company starts illegally importing... calling them seed germinators"; 2001 May BioMed IRB approves pain study; 2002 Jun BioMed terminates the study (two deaths in Florida not properly reported); 2002 Aug FDA finds an infant with cancer treated in LA; 2002 Sep a new IRB, TABS, approves another study; 2003 Mar a 68-year-old woman with heart disease dies on the treatment table after a session at the LA clinic; 2005 Jun FDA terminates the second study; 2007 operators continue. Map total 89 units (Calif. 28, Texas 9, Arizona 7, Florida 6, ...).

Article "Public never warned about dangerous device", 19 Nov 2007, C. Willmsen and M. J. Berens [web]

  • Pappas described as "a math professor from Athens, Greece", age 60 in 2007 (so born about 1947). He calls the PAP-IMI "modern scientific alchemy" and "micro-lightning". He demonstrated it with a chain on his head drawing current from the coil.
  • Pappas quoted: the machine "is absolutely safe", "can cure cancer and AIDS"; "I'm not sure the world is ready to understand the PAP-IMI. It goes beyond known human knowledge."
  • Origin: Pappas met Wallach in California and treated his chronic back pain; "Both claimed the treatment a success". Sold for up to $55,000. 37 study locations.
  • Opposing voices (their characterizations): a California official, "major national health fraud"; ex-staff ("a bunch of cowboys"); an Idaho buyer ("a piece of junk", the plug melted at first switch-on). The FDA investigator Fleckenstein called it one of the most egregious cases in his career.
  • Deaths reported by the paper: two LifeWorks (Clearwater FL) patients who died days after treatment, reported late (Dr Minkoff wrote the "treatments had nothing to do with their demises"); the infant Antonio Campos (cancer); Ellen Green (breast cancer, 2005).
  • "The National Institutes of Health says machines like the PAP-IMI have not been scientifically validated." (as reported)

How this bears on the claims

  • Claim 5 (therapy): the US record 1995-2007 contains no controlled efficacy data. It holds FDA findings of adverse events, the inventor's statements of cure (cancer, AIDS), and testimonials. Under the source-honesty rules the inventor's statements and the regulators' and newspaper's statements are each one side's characterization.
  • Claim 3 (non-ionizing high-energy pulses): FDA reads the output as about 50 J per pulse delivered as a Class III "non-heating diathermy". Later trials give 60-96 J (see pubmed notes).
  • Absence of evidence: the US record goes silent after 2007-2009 because of the regulatory ban and import alert, not because the work stopped. Activity moved to Europe (CE mark), see pubmed and Greek notes.
  • Not reached: the rest of the Seattle Times series (Dec 2007 import ban; Jan 2008 follow-ups), EIR pages 12-17 (exhibit list and FDA-483 items 3-14 in full).